CN101721753B - Absorbable magnesium alloy bracket of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof - Google Patents
Absorbable magnesium alloy bracket of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof Download PDFInfo
- Publication number
- CN101721753B CN101721753B CN200910245022.3A CN200910245022A CN101721753B CN 101721753 B CN101721753 B CN 101721753B CN 200910245022 A CN200910245022 A CN 200910245022A CN 101721753 B CN101721753 B CN 101721753B
- Authority
- CN
- China
- Prior art keywords
- coating
- magnesium alloy
- inorganic
- organic
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011248 coating agent Substances 0.000 title claims abstract description 118
- 238000000576 coating method Methods 0.000 title claims abstract description 118
- 229910000861 Mg alloy Inorganic materials 0.000 title claims abstract description 70
- 239000002131 composite material Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000002421 anti-septic effect Effects 0.000 title claims abstract description 17
- 238000005260 corrosion Methods 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 48
- 230000007797 corrosion Effects 0.000 claims abstract description 44
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 238000007789 sealing Methods 0.000 claims abstract description 33
- 238000007254 oxidation reaction Methods 0.000 claims description 32
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 31
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 230000003647 oxidation Effects 0.000 claims description 27
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 238000013270 controlled release Methods 0.000 claims description 13
- 229930012538 Paclitaxel Natural products 0.000 claims description 11
- 229960001592 paclitaxel Drugs 0.000 claims description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 6
- 239000000919 ceramic Substances 0.000 claims description 5
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000395 magnesium oxide Substances 0.000 claims description 5
- 235000012245 magnesium oxide Nutrition 0.000 claims description 5
- 239000000391 magnesium silicate Substances 0.000 claims description 5
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 5
- 235000019792 magnesium silicate Nutrition 0.000 claims description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910021536 Zeolite Inorganic materials 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical group [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
- 239000010457 zeolite Substances 0.000 claims description 4
- 229910017625 MgSiO Inorganic materials 0.000 claims description 3
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 238000003618 dip coating Methods 0.000 claims description 3
- 238000010147 laser engraving Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052779 Neodymium Inorganic materials 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 108010025899 gelatin film Proteins 0.000 claims description 2
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 2
- KOHFSROUOPQYJK-NOSCCTPQSA-N paclitaxel dichloromethane Chemical compound ClCCl.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 KOHFSROUOPQYJK-NOSCCTPQSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000010410 layer Substances 0.000 abstract description 12
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 7
- 229910001425 magnesium ion Inorganic materials 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 239000002344 surface layer Substances 0.000 abstract 1
- 230000008859 change Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229910045601 alloy Inorganic materials 0.000 description 5
- 239000000956 alloy Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 4
- 229910052726 zirconium Inorganic materials 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- GSWGDDYIUCWADU-UHFFFAOYSA-N aluminum magnesium oxygen(2-) Chemical compound [O--].[Mg++].[Al+3] GSWGDDYIUCWADU-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037148 blood physiology Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical group [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 238000007745 plasma electrolytic oxidation reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention relates to an absorbable magnesium alloy bracket of an inorganic and organic antiseptic biocompatible composite coating and a preparation method thereof. The absorbable magnesium alloy bracket of the inorganic and organic antiseptic biocompatible composite coating comprises a magnesium alloy bracket backbone and a composite coating. The composite coating consists of an inorganic antiseptic coating, a compact organic hole sealing coating, a drug releasing coating and a drug slow release coating; the surface layer of the absorbable magnesium alloy bracket backbone is an inorganic porous antiseptic coating, the compact organic hole sealing coating is arranged outside the inorganic antiseptic coating, the drug releasing coating is arranged outside the compact organic coating, and the drug slow release coating is arranged outside the drug releasing coating. The invention effectively improves the corrosion resistance of the magnesium alloy bracket backbone and controls releasing rate of magnesium ions; meanwhile, the organic membrane layer improves the surface biocompatibility; the degraded products have no side effect, can be absorbed by human bodies, and have good biocompatibility and blood compatibility; and the drug releasing coating can reduce burst release of drug and ensure sustained slow release of drug.
Description
Technical field
The present invention relates to Absorbale magnesium alloy stent of magnesium alloy bracket process for modifying surface, particularly a kind of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof.
Background technology
1964, Dotter etc. proposed the concept of percutaneous transluminal angio plasty, and intended coming support blood vessels unimpeded with blood flow in maintenance blood vessel with silicone rubber or plastics, and 1969, they used becket to do in animal body intravascular stent first.Within 1987, Sigwart has successfully implemented the operation of first case coronary stent.Afterwards, angiocarpy bracket is widely accepted as second milestone in Coronary Artery Disease Intervention Treatment history.At the beginning of 21 century, the bracket for eluting medicament that Cypher and TAXUS be representative of take is applied to clinical the 3rd milestone that be described as.
Intracoronary stening makes restenosis rate significantly drop to 20%-30% from the 30%-60% in balloon dilatation epoch, has become the main method of current Coronary Artery Disease Intervention Treatment.At present, there is nearly 90% coronary artery interventional therapy to comprise implant frame.Although the use of support has greatly reduced restenosis incidence rate, restenosis rate still remains between 10%～30%.In general, desirable intravascular stent should have enough motilities so that support can arrive IC any position; The ability that struts with the good visual and support under assurance minimal damage; On circumference, there is equally distributed intensity and enough rigidity; Can effectively reduce Acute thrombosis and inflammatory reaction; Can stop the formation of new intima and good anticoagulant property and the hydrodynamics compatibility; After implanting 6 months, can automatically disappear and diseased region restenosis can not occur again.Existing support mainly contain bio-medical metal rack, polymer support, radiant stand, can bio-absorbable alloy bracket etc., what metal rack was used at first is bare metal support, although this support can meet mechanical property requirements, but due to its non-biodegradable, long-term implantation can produce inflammatory reaction, simultaneously because blood compatibility is not good and discharge heavy metal ion, may cause a series of potential problems, as chronic inflammatory disease, thrombosis etc., and can not repeat to implant to same diseased region.Research shows that vascular restenosis mainly occurred in initial 3-6 month, after 1 year, rare restenosis occurs, therefore Biodegradable stents arises at the historic moment, this support is support blood vessels chamber within a certain period of time, keep unobstructed blood vessel, after completing corresponding function, Lock-out and catabolite are without any side effect.But the spike of polymer support X ray is undesirable, radial support power is also very poor, larger support thickness and volume, thereby cannot arrive the little blood vessel of far-end, and need to heat while using and resilience force also very large, thereby blood vessel has been caused to potential danger.
Due to metal rack and the intrinsic defect of polymer support, people wish to manufacture support with a kind of alloy that can bio-absorbable.In theory, can bio-absorbable alloy bracket have and improve biological capacitive, strengthen vascular remodeling, rebuild ordinary stent and insert the multiple advantages such as blood vessel power of rear disappearance, can also repeatedly get involved intervention in same lesion, and can not produce the overlapping problem of bringing of support.
Can mainly refer to magnesium alloy by bio-absorbable alloy, magnesium is the interior cation of cell that is only second to potassium in human body, in metabolic processes, plays an important role, and has anticoagulant property and histocompatibility.The advantages such as minimal side effect of the mechanical property that magnesium alloy is good, controlled etching performance and catabolite become the selection of material of support.Magnesium alloy bracket weight is about 3-6mg, degradable in about 2 months, the magnesium ion concentration discharging is far smaller than blood physiology concentration (0.70-1.05mmol/l), and again because magnesium ion shortage can cause cardiovascular disease, the release of support magnesium ion may be more useful.
The use AE21 such as Heublein have been prepared first can bio-absorbable alloy bracket, in zoopery, at aspects such as anticoagulant property, inflammatory reaction, degradation kinetics and endothelialization processes, has all shown good effect.The support that uses improvement magnesium alloy (containing zirconium, yttrium and rare earth element) to prepare again after Biotronik company has all been obtained desirable effect in zoopery and initial stage clinical experiment, has demonstrated huge application potential.
Patent EP1632256-A2 discloses a kind of support of being prepared by magnesium alloy, contains 60-88% magnesium in magnesium alloy, 2-30% rare earth elemental metals, 2-20% yttrium, 0.5-1.5% zirconium, other material of 0-10%.This support has good mechanical performance and biodegradable performance.But this support degradation in vivo excessive velocities, and there is no drug-carried coat.
Chinese patent CN200610130594.3 discloses has Absorbale magnesium alloy stent of double controllable relieasing coating layer and preparation method thereof.This support backbone is the magnesium alloy WE43 that yttrium, neodymium, zirconium and heavy rare earth element ytterbium, erbium, dysprosium and gadolinium form, backbone top layer is the fine and close corrosion-inhibiting coating of magnesium aluminum oxide or cerium oxide, outside be the crosslinked fine and close drug-carried coat that chitosan or collagen protein form, in addition outer is the non-crosslinked drug-carried coat that Poly-L-lactic acid or polyglycolic acid form, and outermost layer is the controlled releasing coating that Poly-L-lactic acid or polyglycolic acid form.This support advantage be that the coating on this support is double controllable relieasing coating layer, in conjunction with firmly, difficult drop-off.
Summary of the invention
The object of the present invention is to provide Absorbale magnesium alloy stent of a kind of new inorganic and organic antiseptic biocompatible composite coating and preparation method thereof, can overcome the defect of prior art.Mg alloy surface is prepared inorganic organic composite antiseptic biocompatible coating and medicament controlled-release coating is coordinated Corrosion Behaviors of Magnesium Alloys and drug delivery problems, inorganic organic composite antiseptic biocompatible coating is mainly comprised of inorganic ceramic film and organic sealing layer, effectively improve the corrosion resistance of magnesium alloy substrate, the different corrosion resistances that not only regulate and control magnesium alloy by preparation method from process conditions, and effectively control the rate of release of magnesium ion, organic film improves the surface biological compatibility simultaneously, catabolite has no side effect simultaneously, can be absorbed by the body, biocompatibility and blood compatibility are good, drug release coating can reduce burst drug release, guarantee that sustained drug slowly discharges.
The Absorbale magnesium alloy stent of a kind of inorganic and organic antiseptic biocompatible composite coating provided by the invention comprises magnesium alloy bracket backbone and composite coating, and the composition of composite coating is:
Inorganic anti-corrosion coating, fine and close organic sealing coating, drug release coating and medicament controlled-release coating;
On Absorbale magnesium alloy stent backbone top layer, being inorganic porous corrosion-inhibiting coating, is fine and close organic sealing coating outside inorganic porous corrosion-inhibiting coating, outside fine and close organic coating, is drug release coating, is medicament controlled-release coating outside drug release coating;
Described inorganic porous corrosion-inhibiting coating is by adopting the method for differential arc oxidation to prepare, and coating main component is comprised of magnesium silicate, magnesium oxide and silicon dioxide, and thickness is 20-30 μ m, and skin is loose and porous structure, and internal layer is fine and close metallurgical binding structure; Fine and close organic sealing coating on inorganic porous corrosion-inhibiting coating is polylactic acid PLLA (weight average molecular weight is 60,000-600,000), adopt the method preparation of spraying or dip-coating, thickness is 10-20 μ m, the PLLA not only micropore of the effective inorganic porous corrosion-inhibiting coating of sealing of hole improves magnesium alloy substrate corrosion resistance, and while biocompatibility is better and degradability is good; Drug release coating is the storage container of drug release, can also effectively discharge medicine by carrying medicaments, is mainly that thickness is 10-20 μ m by the paclitaxel release coat of PLGA (weight average molecular weight the is 4-15 ten thousand) formation of good biocompatibility; Medicament controlled-release coating can effectively reduce the drug releasing rate at drug release initial stage, drug level in the short time of avoiding causing due to burst drug release due to the release initial stage increases, make medicine continue to discharge slowly with finite concentration, medicament controlled-release coating is mainly comprised of cross-linked gelatin film, and thickness is 10-20 μ m.
Described magnesium alloy bracket backbone is to be Y3.7-4.3% by mass fraction, RE (Nd:2.0-2.5%, HeavyE:balance): 2.4-4.4%, the magnesium alloy WE42 that Zr > 0.4% forms.
The preparation method of the Absorbale magnesium alloy stent of a kind of new inorganic and organic antiseptic biocompatible composite coating provided by the invention comprises the following steps:
1) magnesium alloy WE42 is become to support with laser engraving, being then placed in mass concentration is that 1%-10%HCl and mass concentration are 1%-12%FeCl
2pickle in supersound process 5-50 minute, remove the residual chip of processing, then being placed in vacuum drying oven after processing carried out to annealing in process with 800-1500 ℃, with acetone, dehydrated alcohol, deionized water ultrasonic cleaning, after 10 minutes, carry out differential arc oxidation processing successively, the NaOH that differential arc oxidation bath composition is 1-100g/L and the Na of 1-100g/L
2siO
3, oxidization time is 20-120min, electric current density is 0.01-2.0A/cm
2, prepare the MgSiO of perovskite structure
3with zeolite structured SiO
2the inorganic porous corrosion-inhibiting coating that phase and MgO form, this corrosion-inhibiting coating is the ceramic layer of metallurgical binding, be divided into two-layer, internal layer is the ceramic of compact layer with magnesium alloy substrate metallurgical binding, outer is that loose porous layer is followed many micropores and crackle, by changing the oxidation current of differential arc oxidation and the inorganic porous corrosion-inhibiting coating that oxidization time can effectively be prepared different corrosion resistances.After differential arc oxidation, will prop up to be placed in deionized water and carry out ultrasonic cleaning 10-60 minute, room temperature is dried, standby.
2) will be through step 1) prepare contain magnesium silicate, magnesium oxide, then the support of the inorganic porous anticorrosion ceramic structure coating of silicon dioxide is placed in mass concentration is that the dichloromethane solution of 1%-8%PLLA soaks 10min, the fine and close uniform organic PLLA sealing of hole rete of one deck is prepared on the inorganic porous corrosion-inhibiting coating surface that adopts dip-coating method to prepare at differential arc oxidation with constant speed 5cm/min, micropore and the crack on the inorganic porous corrosion-inhibiting coating of the effective sealing of hole of organic PLLA sealing of hole rete surface, strengthen the corrosion resistance of inorganic porous corrosion-inhibiting coating, reduce the nontoxic decomposition that is absorbed by the body of surface roughness and catabolite simultaneously, effectively improved biocompatibility, after rete is dry, use dehydrated alcohol, deionized water ultrasonic cleaning rack surface 5min, make inorganic organic composite antiseptic biocompatible coating.
3) then above-mentioned support is soaked in to about 5-10min in PLGA paclitaxel solution, adopts infusion process to prepare PLGA paclitaxel release coat, after being dried, be placed in again cross-linked gelatin mixed solution, after 5min, take out, dry, prepare cross-linked gelatin controlled release layer.Thereby make to have and corrode Absorbale magnesium alloy stent controlled and medicament slow release while good biocompatibility.
One of characteristic of the present invention is that its bracket coating is inorganic organic composite antiseptic biocompatible coating, this composite coating passes through differential arc oxidation, surface-sealing, organic-inorganic is compound, the methods such as dipping lifts are prepared inorganic organic hybrid films, the corrosion rate regulation and control magnesium ion that inorganic porous corrosion-inhibiting coating is effectively controlled magnesium alloy substrate discharges, surface-sealing film PLLA has not only further improved the anticorrosion ability of the inorganic porous corrosion-inhibiting coating of magnesium alloy, improved the surface biological compatibility of inorganic porous corrosion-inhibiting coating simultaneously, its catabolite is nontoxic to be absorbed by the body, thereby solved magnesium alloy bracket in the implantation too high problem of too fast magnesium ion release concentration of degrading afterwards.Adopting that inorganic and organic coating are mutually compound can extending bracket life period in vivo and effectively change the surface biological compatibility, compares with the support of patent EP1632256-A2, and having solved can the too fast problem of bio-absorbable magnesium alloy bracket degradation rate.
Two of characteristic of the present invention is to prepare organic inorganic composite coating, adopts and controls micro-arc oxidation process parameter, changes PLLA molecular weight, regulates PLLA solution concentration, adds the methods such as micromolecule auxiliary agent and effectively controls Corrosion Behaviors of Magnesium Alloys speed.
Three of characteristic of the present invention is to prepare medicament controlled-release coating when control discharging Corrosion Behaviors of Magnesium Alloys, so not only solved the too fast problem of Corrosion Behaviors of Magnesium Alloys speed but also can controlled release drug.
Accompanying drawing explanation
Fig. 1 is the Absorbale magnesium alloy stent structural representation with the anticorrosion biological coating of inorganic organic composite.
The specific embodiment
Providing embodiments of the invention is below to further illustrate of the present invention, rather than limits the scope of the invention.
As shown in the figure: 1, magnesium alloy bracket backbone; 2, inorganic anti-corrosion coating; 3, the fine and close organic sealing coating of organic PLLA; 4, PLGA taxol drug release coat; 5, cross-linked gelatin medicament controlled-release coating.
By magnesium alloy WE42, (mass fraction is Y3.7-4.3%, RE (Nd:2.0-2.5%, HeavyE:balance): 2.4-4.4%, Zr > 0.4%, Shanxi Mei Ye group) with laser engraving, become support, be then placed on containing mass concentration 7%HCl, mass concentration 8%FeCl
2pickle in supersound process 30 minutes, be placed on again and in vacuum drying oven, carry out annealing in process, with the speed of 3 ℃/min, be warming up to 1100 ℃, keep after 30 minutes, with the speed of 4 ℃/min, be down to after 20 ℃ again, the ultrasonic cleaning instrument that is 500W with power is again dry after deionized water for ultrasonic is cleaned 15 minutes, and the compound coating biology compatibility of cell experiment surface magnesium alloy organic-inorganic is good, and catabolite is nontoxic.
On dried magnesium alloy bracket backbone, prepare inorganic anti-corrosion coating.The method that adopts differential arc oxidation, bath composition is NaOH1-100g/L, Na
2siO
31-100g/L, oxidization time is 20min, 40min, 60min, 80min, 100min, 120min, electric current density is 0.01-2.0A/cm
2.By being shaped with propping up of corrosion-inhibiting coating, be placed on deionized water for ultrasonic cleaning 10 minutes afterwards, room temperature is dried, and obtains being shaped with the MgSiO of perovskite structure
3with zeolite structured SiO
2phase and MgO form the support of the inorganic anti-corrosion coating of (main component: magnesium silicate, magnesium oxide and silicon dioxide), and coating layer thickness is 20-30 μ m.
A certain amount of PLLA is joined to CH
2cl
2in solvent, configuration concentration is the PLLA hole sealing solution of 1-10% (W/V).
Adopt dipping-pulling method to carry out sealing of hole processing to magnesium alloy differential arc oxidation coating, be about to sample and immerse 1min in PLLA solution, then with the speed of 5cm/min, mention equably, allow bottom polymer solution fall to the greatest extent, room temperature is dried, after in 40 ℃ of baking ovens dry 24h, the inorganic organic composite coating of bio-compatible degradable of the PLLA sealing of hole of system, thickness is 10-20 μ m.
Preparation is dissolved in a certain amount of paclitaxel and PLGA in dichloromethane solution, preparing drug quality concentration is the PLGA/ paclitaxel dichloromethane solution of 4-12%, the support of above-mentioned PLLA sealing of hole is soaked in PLGA/ paclitaxel mixed solution, after 10min, take out, after dry, make the PLGA/ taxol drug release coat that thickness is 10-20 μ m, then by above-mentioned gelatin solution that is placed on 0.1-3% glutaraldehyde cross-linking, after 5min, take out, dry, making thickness is the cross-linked gelatin controlled-release coating of 10-20 μ m.
The support making is tested in 37 ℃ of Artificial Bodys, after result demonstration PLLA sealing of hole, the corrosion resistance of inorganic organic composite coating magnesium alloy bracket is far above the corrosion resistance of the inorganic coating magnesium alloy bracket that sealing of hole is not processed, the change differential arc oxidation time can change corrosion resistance of magnesium alloy, differential arc oxidation corrosion impedance is the highest brings up to 30 times of corrosion impedance of magnesium alloy substrate, , the change differential arc oxidation time can be controlled the corrosion-resistant intensity of magnesium alloy inoranic membrane, polymer coating was degraded complete in 180 days, metal rack was degraded complete in 310 days, drug release shows, in the time of 30 days, drug release only has 20%, there is no burst drug release simultaneously, drug release is slow.
Experiment condition and operating process are identical with embodiment 1, in preparing the process of differential arc oxidation inorganic coating, change oxidization time into 20-120min, oxidation current changes 0.01A, 0.05A, 0.1A, 0.2A, 0.4A, 0.6A, 0.8A, 1.0A, 1.2A, 1.4A, 1.6A, 2.0A into, the compound coating biology compatibility of cell experiment surface magnesium alloy organic-inorganic is good, and catabolite is nontoxic.
The support making is tested in 37 ℃ of Artificial Bodys, result shows that the corrosion resistance of inorganic organic composite coating magnesium alloy bracket prepared by PLLA sealing of hole is far above the corrosion resistance of the inorganic coating magnesium alloy bracket that sealing of hole is not processed, change current parameters and can change corrosion resistance of magnesium alloy, differential arc oxidation electric current density 0.5A corrosion impedance is 30 times of corrosion impedance of magnesium alloy substrate, polymer coating was degraded complete in 180 days, and metal rack was degraded complete in 310 days.
Experiment condition and operating process are identical with embodiment 1, and just changing the differential arc oxidation time is 20-120min, oxidation current density be 0.01-2.0A cm
2, similar to 2 to embodiment 1, just change: in the process of the organic PLLA hole sealing coating of preparation, change PLLA molecular weight, the compound coating biology compatibility of cell experiment surface magnesium alloy organic-inorganic is good, and catabolite is nontoxic.
The support making is tested in 37 ℃ of Artificial Bodys, and result shows the degradation cycle difference of the PLLA sealing of hole magnesium alloy of different molecular weight, and polymer coating was degraded complete in 150-360 days, and metal rack was degraded complete in 240-420 days.
Embodiment 4
Experiment condition and operating process are identical with embodiment 1, just change differential arc oxidation time 20-120min, oxidation current density be 0.01-2.0A cm
2similar to 2 to embodiment 1, just change in the process of the organic PLLA hole sealing coating of preparation, add the PEG auxiliary agent of different content, thereby by PEG content number regulate the degradability of PLLA to control PLLA the effect of inorganic coating sealing of hole to be reached to the effect of controlling magnesium alloy bracket corrosion rate, the compound coating biology compatibility of cell experiment surface magnesium alloy organic-inorganic is good, and catabolite is nontoxic.
The support making is tested in 37 ℃ of Artificial Bodys, result shows that the PLLA degradation cycle of different PEG content is different, different to the corrosion-resisting function of magnesium alloy differential arc oxidation film, polymer coating was degraded complete in 155-330 days, and metal rack was degraded complete in 238-380 days.
Experiment condition and operating process are identical with embodiment 1, just change differential arc oxidation time 10-120min, oxidation current density be 0.01-2.0A cm
2similar to 2 to embodiment 1, just change: in the process of the organic PLLA hole sealing coating of preparation, PLLA impregnation liquid by preparation different molecular weight changes sealing of hole rete, thereby control magnesium alloy bracket corrosion rate, the compound coating biology compatibility of cell experiment surface magnesium alloy organic-inorganic is good, and catabolite is nontoxic.The support making is tested in 37 ℃ of Artificial Bodys, and result shows the degradation cycle difference of the PLLA sealing of hole magnesium alloy of different molecular weight, and polymer coating was degraded complete in 155-345 days, and metal rack was degraded complete in 240-388 days.
Claims (4)
1. the Absorbale magnesium alloy stent of an inorganic and organic antiseptic biocompatible composite coating, comprise magnesium alloy bracket backbone and composite coating, the composition of composite coating contains inorganic porous corrosion-inhibiting coating, on Absorbale magnesium alloy stent backbone top layer, be inorganic porous corrosion-inhibiting coating, it is characterized in that also containing fine and close organic sealing coating, drug release coating and medicament controlled-release coating; Inorganic anti-corrosion coating is comprised of the magnesium silicate of perovskite structure, zeolite structured silicon dioxide and magnesium oxide; Outside inorganic porous corrosion-inhibiting coating, being fine and close organic sealing coating, is drug release coating outside fine and close organic sealing coating, is medicament controlled-release coating outside drug release coating;
Described fine and close organic sealing coating is polylactic acid PLLA, and weight average molecular weight is 60,000-600,000, adopts the method preparation of spraying or dip-coating, and thickness is 10-20 μ m;
Described drug release coating is the paclitaxel release coat that the PLGA by good biocompatibility forms, and wherein the weight average molecular weight of PLGA is 4-15 ten thousand, and the thickness of described drug release coating is 10-20 μ m; Described medicament controlled-release coating is comprised of cross-linked gelatin film, and thickness is 10-20 μ m;
The yttrium that described magnesium alloy bracket backbone is 3.7-4.3% by mass fraction, the rare earth element of 2.4-4.4% and be greater than the magnesium alloy WE42 that 0.4% zirconium forms, in its rare earth elements containing neodymium and the balanced heavy rare earth element forming of 2.0-2.5%.
2. a preparation method for the Absorbale magnesium alloy stent of inorganic and organic antiseptic biocompatible composite coating claimed in claim 1, is characterized in that comprising following process:
1) magnesium alloy WE42 is become to support with laser engraving, being then placed in mass concentration is that 1%-10%HCl and mass concentration are 1%-12%FeCl
2pickle in supersound process 5-50 minute, remove the residual chip of processing, then being placed in vacuum drying oven after processing carried out to annealing in process with 800-1500 ℃, with acetone, dehydrated alcohol, deionized water ultrasonic cleaning, after 10 minutes, carry out differential arc oxidation processing successively, prepare the MgSiO of perovskite structure
3with zeolite structured SiO
2the inorganic porous corrosion-inhibiting coating that phase and MgO form, will prop up to be placed in deionized water after differential arc oxidation and carry out ultrasonic cleaning 10-60 minute, and room temperature is dried, standby; The condition that differential arc oxidation is processed is: the NaOH that differential arc oxidation bath composition is 1-100g/L and the Na of 1-100g/L
2siO
3, oxidization time is 10-200 minute, electric current density is 0.01-2.0A/cm
2;
2) by through step 1) to be then placed in mass concentration be that the dichloromethane solution of 1%-8%PLLA soaks 1min for the support of the inorganic porous anticorrosion ceramic structure coating that contains magnesium silicate, magnesium oxide, silicon dioxide prepared, with constant speed 5cm/min, lift and prepare organic PLLA sealing of hole rete, after rete is dry, use dehydrated alcohol, deionized water ultrasonic cleaning rack surface 5min;
3) then above-mentioned support is soaked in to 5-10min in PLGA paclitaxel solution, prepares PLGA paclitaxel release coat, after being dried, be placed in again cross-linked gelatin mixed solution, after 5min, take out, dry.
3. according to preparation method claimed in claim 2, it is characterized in that step 2) described rete is dry is dry 24h in 40 ℃ of baking ovens.
4. according to preparation method claimed in claim 2, it is characterized in that step 3) be that mass concentration is the PLGA/ paclitaxel dichloromethane solution of 4-12% in described PLGA paclitaxel solution, described cross-linked gelatin mixed solution is the gelatin solution of 0.1-3% glutaraldehyde cross-linking.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910245022.3A CN101721753B (en) | 2009-12-23 | 2009-12-23 | Absorbable magnesium alloy bracket of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910245022.3A CN101721753B (en) | 2009-12-23 | 2009-12-23 | Absorbable magnesium alloy bracket of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101721753A CN101721753A (en) | 2010-06-09 |
| CN101721753B true CN101721753B (en) | 2014-04-09 |
Family
ID=42443693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910245022.3A Expired - Fee Related CN101721753B (en) | 2009-12-23 | 2009-12-23 | Absorbable magnesium alloy bracket of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101721753B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016010541A1 (en) * | 2014-07-17 | 2016-01-21 | Dolan Shawn E | Electroceramic coating for magnesium alloys |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103132045A (en) * | 2011-11-28 | 2013-06-05 | 英作纳米科技（北京）有限公司 | Preparation method for coatings of medical supplies and products thereof |
| CN102908675A (en) * | 2012-10-29 | 2013-02-06 | 东南大学 | Absorbable suture nail for anastomat |
| CN106676608B (en) * | 2016-11-22 | 2018-06-26 | 佳木斯大学 | A kind of medical pure magnesium surface electrophoretic deposition carries the preparation method of medicine coating in induction of bone growth |
| CN106521601B (en) * | 2016-11-22 | 2018-08-10 | 佳木斯大学 | The preparation method of medicine coating during a kind of pure titanium mouth cavity planting body differential arc oxidation-DOPA amine coupling carries |
| CN106521603B (en) * | 2016-11-22 | 2018-06-26 | 佳木斯大学 | A kind of medical pure magnesium surface coupling carries the preparation method of medicine coating in induction of bone growth |
| CN107412856A (en) * | 2017-08-03 | 2017-12-01 | 上海长海医院 | Nano-pore magnesium silicate microballoon/poly butylene succinate compound rest, protein coating compound rest and preparation method and application |
| CN110241453A (en) * | 2019-04-25 | 2019-09-17 | 西南大学 | A kind of release fluoride and the degradable kirsite bone nail of cerium and preparation method thereof |
| CN110760916B (en) * | 2019-11-18 | 2022-04-05 | 和县科嘉阀门铸造有限公司 | Method for improving corrosion resistance of magnesium alloy valve |
| CN115627512A (en) * | 2022-11-18 | 2023-01-20 | 东莞宜安科技股份有限公司 | Biomedical magnesium alloy composite coating and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1465410A (en) * | 2002-06-27 | 2004-01-07 | 微创医疗器械(上海)有限公司 | Drug-eluting stent (DES) with multicoating |
| CN1524590A (en) * | 2003-02-28 | 2004-09-01 | 微创医疗器械(上海)有限公司 | Medicament elution interventional medical apparatus and preparing method thereof |
| CN101214396A (en) * | 2008-01-03 | 2008-07-09 | 乐普（北京）医疗器械股份有限公司 | Controlled degradation magnesium alloy coating bracket and preparation thereof |
| CN101239009A (en) * | 2008-01-29 | 2008-08-13 | 乐普（北京）医疗器械股份有限公司 | Controlled degradation differential arc oxidized metallic support and manufacture method thereof |
-
2009
- 2009-12-23 CN CN200910245022.3A patent/CN101721753B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1465410A (en) * | 2002-06-27 | 2004-01-07 | 微创医疗器械(上海)有限公司 | Drug-eluting stent (DES) with multicoating |
| CN1524590A (en) * | 2003-02-28 | 2004-09-01 | 微创医疗器械(上海)有限公司 | Medicament elution interventional medical apparatus and preparing method thereof |
| CN101214396A (en) * | 2008-01-03 | 2008-07-09 | 乐普（北京）医疗器械股份有限公司 | Controlled degradation magnesium alloy coating bracket and preparation thereof |
| CN101239009A (en) * | 2008-01-29 | 2008-08-13 | 乐普（北京）医疗器械股份有限公司 | Controlled degradation differential arc oxidized metallic support and manufacture method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李绮等.可降解镁合金表面载药涂层的制备和性能.《材料研究学报》.2009,第23卷(第3期),300-303. * |
| 许鑫华等.医用镁合金的生物腐蚀及高分子涂层处理.《稀有金属材料与工程》.2008,第37卷(第7期),1225-1228. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016010541A1 (en) * | 2014-07-17 | 2016-01-21 | Dolan Shawn E | Electroceramic coating for magnesium alloys |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101721753A (en) | 2010-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101721753B (en) | Absorbable magnesium alloy bracket of inorganic and organic antiseptic biocompatible composite coating and preparation method thereof | |
| CN101721266B (en) | Absorbable magnesium alloy stent of anticorrosion and drug release composite coating and preparation method thereof | |
| US8603569B2 (en) | Implant and method for producing a degradation-inhibiting layer on the surface of an implant body | |
| US8337936B2 (en) | Implant and method for manufacturing same | |
| CN100488575C (en) | Absorble magnesium alloy stent possessing double controlledly released coating layer and its preparation method | |
| CN104784750B (en) | Improve the corrosion proof surface modifying method of morphotropism Biological magnesium alloy implant devices | |
| US9259516B2 (en) | Implant and method for manufacturing | |
| CN104056307B (en) | A kind of development degradable polymer support and preparation method thereof | |
| US20070181433A1 (en) | Metallic composite coatings for delivery of therapeutic agents from the surface of implantable devices | |
| US8071156B2 (en) | Endoprostheses | |
| US9878072B2 (en) | Bioabsorbable medical device or medical device component and preparation method thereof | |
| US9433709B2 (en) | Interventional medical device and manufacturing method thereof | |
| EP2762111A1 (en) | Interventional medical device and manufacturing method thereof | |
| CN102908216A (en) | Biodegradable medical human body cavity channel inner bracket and preparation method thereof | |
| CN110234366A (en) | High functional biological bioabsorbable stent | |
| CN101869723A (en) | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method | |
| CN101785880B (en) | Blood vessel bracket utilizing titanium oxide nanotube to load medicine | |
| CN114767950B (en) | Corrosion-resistant and drug-loaded composite coating for magnesium alloy stent and preparation method thereof | |
| US20130004548A1 (en) | Medical devices having pharmacological active agent releasing material | |
| WO2020146840A1 (en) | Titanium dioxide coatings for medical devices made by atomic layer deposition | |
| JP2008125622A (en) | Biodegradable magnesium material | |
| CN107913119A (en) | A kind of interventional medical device and preparation method thereof | |
| KR102641376B1 (en) | Absorbable implant device | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| CN103272290B (en) | Absorbable magnesium alloy stent with polymer and TiO2 nanotube coating and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220401 Address after: 300304 room 1-2050, Block E, No. 6, Huafeng Road, Huaming high tech Industrial Zone, Dongli District, Tianjin Patentee after: Zhongzhi online Co.,Ltd. Address before: 300072 Tianjin City, Nankai District Wei Jin Road No. 92 Patentee before: Tianjin University |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100609 Assignee: TIANJIN KUANDA AQUATIC FOOD CO.,LTD. Assignor: Zhongzhi online Co.,Ltd. Contract record no.: X2022120000052 Denomination of invention: Absorbable magnesium alloy scaffold with inorganic organic anti-corrosion biocompatible composite coating and its preparation method Granted publication date: 20140409 License type: Common License Record date: 20221129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140409 |